Vensica Medical Raises $11M for Phase 2 Overactive Bladder Trials

Vensica Medical, a trailblazing company specializing in urology therapeutics, has announced the successful completion of an $11 million funding round. This significant investment will support the company's forthcoming Phase 2 clinical trials in the United States and Europe, focusing on their innovative treatment for overactive bladder (OAB) using botulinum toxin A (Xeomin®). This therapy will be administered through Vensica's proprietary, needle-free device.

The funding round was spearheaded by Israel Biotech Fund (IBF) and included strategic contributions from Merz, a prominent entity in the neurotoxin field, and Laborie, a well-known name in medical devices for urology. This financial boost is expected to propel Vensica forward in its mission to offer a minimally invasive, efficient, and patient-friendly solution for those suffering from OAB.

Vensica's groundbreaking technology utilizes a needle-free drug delivery system that administers Xeomin® directly to the bladder wall. This method promises to provide a more comfortable and less invasive alternative to traditional injection treatments, potentially setting a new standard for OAB care. The needle-free system is also envisioned as a versatile platform for addressing other bladder-related conditions in the future.

"We are delighted to have the backing of such esteemed investors and partners who believe in our vision for revolutionizing overactive bladder treatment," said Avner Geva, CEO of Vensica. "This funding empowers us to advance our Phase 2 trials and brings us closer to offering this cutting-edge therapy to the patients who need it."

Through its strategic partnership with Merz, Vensica has secured exclusive rights to use Xeomin® in needle-free applications for various urological conditions and will benefit from Merz's clinical development expertise. This collaboration represents a significant milestone in Vensica's journey towards delivering next-generation urology treatments.

Vensica Medical, established within The Trendlines Group incubator program, is focused on the development of innovative therapies for urological ailments. The company's flagship product is a needle-free delivery system for Xeomin® (botulinum toxin A), aimed at providing a minimally invasive treatment for overactive bladder. This recent investment and strategic alliances underscore Vensica's commitment to transforming the landscape of urological care.